|
Sign In to gain access to subscriptions and/or personal tools.
|
National health care costs of peripheral arterial disease in the Medicare population
Alan T Hirsch
Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA; Minneapolis Heart Institute Foundation, Minneapolis, MN, USA hirsc005{at}umn.edu
Lacey Hartman
Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA
Robert J Town
Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA
Beth A Virnig
Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA
Abstract
Lower extremity peripheral arterial disease (PAD) is prevalent in the Medicare population and is associated with high rates of myocardial infarction, stroke, amputation, and death. Nevertheless, national health expenditures for PAD are not known. We hypothesized that PAD-related costs are high, increase with age, and that treatment rates would be less than known PAD prevalence. The objective was to determine national health care expenditures for PAD in the United States. PAD-related treatment costs were calculated in the elderly, non-disabled Medicare population. The cost analysis relied on the 5% control population for the linked SEER-Medicare data and Medicare claims for the calendar year 2001, identifying PAD cases based on diagnosis and procedure codes. Costs were aggregated separately for inpatient and outpatient treatment and estimates adjusted to reflect the Medicare population. A total of $4.37 billion was spent on PAD-related treatment and 88% of expenditures were for inpatient care. Medicare program outlays totaled $3.87 billion, while enrollees (or their supplemental insurance) spent the remaining $500 million. In total, 6.8% of the elderly Medicare population received treatment for PAD. Treatment increased with age at rates of 4.5%, 7.5%, and 11.8% for individuals aged 65–74, 75–84, and >85 years, respectively. PAD-related costs accounted for approximately 13% of all Medicare Part A and B expenditures for the PAD-treated cohort, and 2.3% of total Medicare Part A and B expenditures. In conclusion, US national PAD-related costs are high, associated with inpatient care, and increase with age. PAD is treated at rates lower than the known PAD prevalence as only approximately one-third of the population with known PAD had detectable PAD-related health care costs in our analysis. The potential impact of earlier PAD detection and use of outpatient preventive strategies on total national PAD health care costs is unknown.
Key Words: atherosclerosis • cardiovascular diseases • cost • health economics • Medicare • peripheral arterial disease • population
References
- 1 Hiatt WR . Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608–1621.[Free Full Text]
- 2 Tunis SR Bass EB Steinberg EP . The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med 1991; 325: 556–563.[Abstract]
- 3 Criqui MH Langer RD Fronek A . Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–386.[Abstract]
- 4 Newman AB Sutton-Tyrrell K Vogt MT Kuller LH . Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487–489.[Abstract/Free Full Text]
- 5 Hirsch AT Haskal ZJ Hertzer NR . ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease [Lower Extremity, renal, Mesenteric, and Abdominal Aortic]). Circulation 2006; 113: 1474–1547.[Free Full Text]
- 6 Criqui MH Fronek A Barrett-Connor E . The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510–515.[Abstract/Free Full Text]
- 7 Hirsch AT Halverson SL Treat-Jacobson D . The Minnesota regional peripheral arterial disease screening program: toward a definition of community standards of care. Vasc Med 2001; 6: 87–96.[Abstract/Free Full Text]
- 8 Marso SP Hiatt WR . Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47: 921–929.[Abstract/Free Full Text]
- 9 Dormandy JA Rutherford RB . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1–S296.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 10 Feringa HHH van Waning VH Bax JJ . Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47: 1182–1187.[Abstract/Free Full Text]
- 11 Margolis J Barron JJ Grochulski WD . Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005; 11: 727–734.[Medline]
[Order article via Infotrieve]
- 12 Strom BL . Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001; 10: 389–392.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 13 Czaykowski PM Moore MJ Tannock IF . High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160: 2021–2024.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 14 Grenader T Shavit L Ospovat I Gutfeld O Peretz T . Aortic occlusion in patients treated with cisplatin-based chemotherapy. Mt Sinai J Med 2006; 75: 810–812.
- 15 Weijl NI Rutten MF Zwinderman AH . Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18: 2169–2178.[Abstract/Free Full Text]
- 16 Mathews J Goel R Evans WK . Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Cancer Chemother Pharmacol 1997; 40: 19–22.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 17 Numico G Garrone O Dongiovanni V . Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103: 994–999.[Medline]
[Order article via Infotrieve]
- 18 Thom T Haase N Rosamond W . American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85–e151.[Free Full Text]
- 19 Medicare and Medicaid Statistical Supplement. U.S. Department of Health and Human Services, Health Care Financing Administration. Health Care Financ Rev Stat Suppl 2004. http://www.cms.hhs.gov/MedicareMedicaidStatSupp/LT/list.asp#TopOfPage.
- 20 Leng GC Lee AJ Fowkes FG . Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996; 25: 1172–1181.[Abstract/Free Full Text]
- 21 Newman AB Shemanski L Manolio TA . Ankle–arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19: 538–545.[Abstract/Free Full Text]
- 22 Selvin E Erlinger TP . Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004; 110: 738–743.[Abstract/Free Full Text]
- 23 Wildman RP Muntner P Chen J . Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002. Am J Cardiol 2005; 96: 1579–1583.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 24 Wattanakit K Folsom AR Selvin E . Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC). Study. Atherosclerosis 2005; 180: 389–397.[CrossRef]
- 25 Migliaccio-Walle K Caro JJ Khajak I O'Brien JA . Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005; 23: 733–742.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 26 Pedersen TR Kjekshus J Pyorala K . Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333–335.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 27 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 28 Currie CJ Morgan CL Peters JR . The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998; 21: 42–48.[Abstract]
- 29 Gardner AW Poehlman ET . Exercise programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975–980.[Abstract/Free Full Text]
- 30 Ludvig J Miner B Eisenberg MJ . Smoking cessation in patients with coronary artery disease. Am Heart J 2005; 149: 565–572.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 31 Sdringola S Nakagawa K Nakagawa Y . Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 2003; 41: 263–272.[Abstract/Free Full Text]
Vascular Medicine, Vol. 13, No. 3,
209-215 (2008)
DOI: 10.1177/1358863X08089277
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
W. R. Hiatt
Can Measuring the Ankle-Brachial Index Improve Public Health?
J. Am. Coll. Cardiol.,
November 18, 2008;
52(21):
1743 - 1744.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Henry, R. S. Schwartz, and A. T. Hirsch
"POBA Plus": Will the Balloon Regain Its Luster?
Circulation,
September 23, 2008;
118(13):
1309 - 1311.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Durand-Zaleski
Why cost-of-illness studies are important and inform policy
Vascular Medicine,
August 1, 2008;
13(3):
251 - 253.
[PDF]
|
|
|
|
|
